XSTO
FLERIE
, Last price
SEK
Name
InDex Pharmaceuticals Holding AB
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
26.91%
Rev. 5Y
202.05%
Div Yld LY
—
Div Yld TTM
—
Revenues
9m
+8,700.00%
Net income
-757m
L+231.97%
CFO
-28m
L+65.29%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Flerie AB (publ) functions as a venture capital entity, concentrating its investments on nascent businesses. The firm actively seeks to fund biotechnology and pharmaceutical companies dedicated to advancing drug discovery and development, or producing innovative tools and applications aimed at addressing pressing global health concerns. Geographically, their investment scope includes Europe, the United States, and Israel. Founded in 2011, Flerie AB (publ) is headquartered in Stockholm, Sweden, and also operates a branch office in London, United Kingdom.
Related entities
Subsidiaries
Flerie Invest AB
Key people
Peter Zerhouni
Chief Executive Officer · since 2016
Chief Financial Officer · since 2017
Thomas Knittel
Chief Medical Officer
Director · since 2016
Independent Director · since 2016
Headquarters & legal address
Skeppsbron 16
Stockholm, AB 111 30
SE
Stockholm, AB 111 30
SE
Previous name
InDex Pharmaceuticals Holding AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||